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Abstract 
Objective: To assess in vivo the expression of phosphodiesterase 4 (PDE4) and its 
relevance to cognitive symptoms in Parkinson’s disease (PD) patients using 
[11C]rolipram PET. 
Methods: We studied 12 levodopa-treated PD patients with no concurrent diagnosis 
of mild cognitive impairment or dementia. Their data were compared to those from 12 
healthy controls. All participants underwent neuropsychiatric and cognitive 
assessment using the Cambridge Neuropsychological Test Automated Battery 
(CANTAB®).  Parametric images of [11C]rolipram volume of distribution (VT) values 
were determined with the Logan plot. 
Results: PD patients performed worse than healthy controls in cognitive 
examinations assessing psychomotor speed, episodic memory, and spatial working 
memory and executive function. PD patients showed reductions in [11C]rolipram VT 
compared to healthy controls, in the caudate (28%), thalamus (23%), hypothalamus 
(32%) and in the cortex (16%). Within thalamic sub-regions [11C]rolipram VT values 
in PD patients were decreased by 12-32% with most marked decreases observed in 
prefrontal and temporal thalamic nuclei whereas motor nuclei were the less affected. 
Within the cortex [11C]rolipram VT values in PD patients were decreased by 11-20% 
with most marked decreases observed in posterior dorsolateral frontal cortex, medial 
frontal cortex and supplementary motor area, whereas orbitofrontal cortex was less 
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affected. Worse performance in spatial working memory correlated with lower 
[11C]rolipram VT values in posterior dorsolateral frontal cortex, medial frontal cortex, 
supplementary motor area, precentral gyrus, caudate, and prefrontal thalamic nuclei. 
Conclusions: Our findings demonstrate loss of PDE4 expression in the striato-
thalamo-cortical circuit, which is associated with deficits of spatial working memory 
in PD patients. 
 
Introduction 
Patients with Parkinson’s disease (PD) carry a six-fold increased risk of developing 
dementia compared to the general population (1). Spatial working memory is an 
executive function that typically is impaired early in the course of PD (2, 3). The 
Parkinson Associated Risk Syndrome (PARS) study has shown impaired working 
memory in individuals at risk for developing PD suggesting that these subdomain 
cognitive deficits may be part of the PD premotor stage (4). 
 
Phosphodiesterase 4 (PDE4) is an intracellular enzyme expressed in neurons and glial 
cells, where it hydrolyses cAMP (5). PDE4 regulates the cAMP–PKA–cAMP 
response element binding protein (CREB) pathway, and modulates the transcription 
of proteins involved in synaptic plasticity and memory process (6). Long-lasting 
plasticity and memory deficits can be caused by abnormal and sustained activation of 
cAMP/PKA signalling (7). Disinhibition of cAMP/PKA signalling occurs in the 
prefrontal cortex of aged rats and monkeys with working memory deficits suggesting 
a key role of cAMP/PKA pathways in the modulation of executive dysfunction (7).  
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Here, we investigated in vivo the expression of PDE4 and its relevance to cognitive 
deficits in PD patients, using PET with [11C]rolipram, which is a selective PDE4 
radioligand for human use (8).  As age-related reduction in PDE4 expression in 
healthy individuals older than 55 years old has not been investigated, we also 
explored the influence of age in our cohort of healthy controls. 
 
Our findings suggest loss of PDE4 expression in striato-thalamo-cortical network in 
patients with PD, which is associated with working memory deficits. 
 
Materials and methods 
Participants and clinical characteristics  
Twelve patients with a diagnosis of idiopathic PD according to the Queen Square 
Brain Bank criteria were recruited from specialist Movement Disorders clinics at the 
National Hospital of Neurology & Neurosurgery, Queen Square, London (Table 1). 
None of these patients fulfilled the diagnostic criteria of PD mild cognitive 
impairment or PD dementia (9, 10).  
 
Twelve healthy individuals with no history of neurological or psychiatric disorders 
were recruited as control group. To assess the effect of age on PDE4 expression, we 
studied a younger (n=6; 5 males; mean age ±SD=39.0±8.4; age range=26-52 years 
old) and an older (n=6; 5 males; mean age ±SD= 66.3±3.6; age range=53-78 years 
old) subgroup of healthy controls.   
 
All participants had no history of other neurological or psychiatric disorders, were not 
taking substances with known actions in PDEs (e.g. apremilast, cilomilast, luteolin, 
 6 
piclamilast, roflumilast and ibudilast), and had no contraindications to undertake PET 
and MRI scanning according to scanning safety criteria (http://www.mrisafety.com; 
https://www.gov.uk/government/publications/arsac-notes-for-guidance). 
 
PD patients were all on levodopa treatment. Daily and lifetime dopaminergic 
medication dose was calculated with a formula based on the theoretical equivalence to 
levodopa (11). Motor symptom severity was assessed with the Unified PD Rating 
Scale part-III (UPDRS-III) and according to Hoehn & Yahr stage. Motor assessments 
were performed OFF medication after overnight withdrawal of patient’s dopaminergic 
medications. Neuropsychiatric symptoms were assessed with the Apathy Evaluation 
Scale, Beck Depression Inventory-II (BDI-II), and the Hamilton Depression Rating 
Scale (HDRS). Non-motor Symptoms Scale for PD was used to assess non-motor 
symptoms. The Mini Mental Status Examination (MMSE) and Montreal Cognitive 
Assessment (MoCA) were used to assess general cognitive status. Further cognitive 
assessments were carried out using the CANTAB® and included assessments related 
to psychomotor speed (Reaction Time), attention (Rapid Visual Information 
Processing), episodic memory (Paired Associate Learning and Delayed Match to 
Sample), working memory and executive function (Spatial Working Memory; 
Supplemental Material). CANTAB® neuropsychological tests have been previously 
described in detail (12) and shown to be highly sensitive to deterioration in executive 
function in PD (13). Quality of life was measured with the patient self-reported 39-
item PD Questionnaire (PDQ-39). 
 
Standard Protocol Approvals, Registrations, and Patient Consents  
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The study was approved by the institutional review boards and the research ethics 
committee. Written informed consent was obtained from all study participants in 
accordance with the Declaration of Helsinki. 
 
Imaging data analysis 
MRI-based volumetric analysis 
Since PDE4 is an intracellular enzyme, neuronal loss may affect PDE4 availability as 
measured with PET.  We investigated volumetric changes in cortical and subcortical 
nuclei regions in our cohort of PD patients compared to all healthy controls. 
FreeSurfer image analysis suite (version 5.3.0 http://surfer.nmr.mgh.harvard.edu) was 
used to process individual MRI scans, to derive measures of cortical thickness and 
subcortical nuclei volumes (Supplemental methods).  
 
[11C]rolipram PET data analysis 
The Molecular Imaging and Kinetic Analysis Toolbox software package 
(MIAKATTM: www.miakat.org; 14), implemented in MATLAB® (The Mathworks, 
Natick, MA, USA) was used to carry out image processing and kinetic modelling. 
MIAKAT™ combines in-house code with wrappers for FMRIB Software Library 
(FSL, http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/) and Statistical Parametric Mapping (SPM, 
http://www.fil.ion.ucl.ac.uk/spm/) commands in order to provide state-of-the-art 
functionality within a coherent analysis framework. The MIAKATTM processing 
pipeline was followed, ensuring that all quality control steps were completed to 
generate both parametric images and regional estimates of [11C]rolipram volume of 
distribution (VT; Supplemental methods). The anatomical CIC atlas version 2.0 (15) 
was used to define regions of interest (ROIs).   
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Statistical analysis 
Statistical analysis and graph illustration were performed with SPSS (version 20 
Chicago, Illinois, USA) and GraphPad Prism (version 6.0c) for MAC OS X, 
respectively. For all variables, variance homogeneity and Gaussianity were tested 
with Bartlett and Kolmogorov-Smirnov tests. Two-tailed t-test (parametric variables) 
and Mann-Whitney U test (non-parametric variables) were used for between-group 
comparisons, as appropriate. P values for each variable were calculated following 
Benjamini-Hochberg multiple-comparisons test in order to reduce false discovery 
rate. We set the false discovery rate cut-off at 0.05. We interrogated correlations 
between PET and clinical data using Spearman’s r correlation coefficient and we 
applied the Benjamini-Hochberg correction. All data are presented as mean±SD, and 
the level α was set for all comparisons at P<0.05, Benjamini-Hochberg corrected.  
 
Results 
Cognitive and neuropsychiatric function 
PD patients performed worse than healthy controls in the assessments of psychomotor 
speed [five choice median reaction time (Puncor=0.014; Padj=0.012) and median 
movement time (Puncor<0.001; Padj<0.001)], episodic memory [delayed match to 
sample % correct (Puncor=0.003; Padj=0.006)], and working memory and executive 
function [spatial working memory between errors (Puncor=0.016; Padj=0.031)] (Table 
e-1).  
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Neuropsychiatric assessments showed significant differences between healthy 
controls and PD patients (BDI-II: P<0.05; HDRS: P<0.05); however, the 
neuropsychiatric burden in our cohort of PD patients was minimal and did not meet 
the cut-off score for depression. 
 
Volumetric analysis 
Freesurfer analysis showed no volumetric differences in cortical and subcortical 
nuclei ROIs between the groups of PD patients and all healthy controls (Table e-2). 
Moreover, no significant associations were observed between cortical and subcortical 
volumes and [11C]rolipram VT for the whole brain analysis in the group of healthy 
controls (P>0.10 for all brain regions). 
 
 
Effect of age on PDE4 expression 
We found no significant differences in cortical and subcortical nuclei [11C]rolipram 
VT between the group of younger and older healthy control subgroups (all P>0.10; 
Table e-3). Moreover, in the group of healthy controls there were no significant 
associations between age and [11C]rolipram VT for any brain region (P>0.18 for all 
brain regions). 
 
Effect of medication on PDE4 expression 
We did not find any interactions between daily and lifetime levodopa equivalent dose 
measured in total or for levodopa or dopamine agonist medications separately, and 
[11C]rolipram VT  in all the regions of interested examined (P>0.10). 
 
 
PDE4 expression in Parkinson’s patients 
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We found 5-32% decreases in [11C]rolipram VT in PD patients compared to the group 
of healthy controls. PD patients had significantly lower mean [11C]rolipram VT in 
subcortical nuclei (Table e-4; Figures 1A, 2 and 3) and frontal cortex regions (Table 
e-4; Figures 1B, 2 and 3). Although [11C]rolipram VT was lower in all cortical regions, 
there were no significant differences in [11C]rolipram VT between the patients with PD 
and healthy controls in parietal, temporal and occipital cortices (all P>0.10). 
 
PD patients had significantly lower mean [11C]rolipram VT in the caudate, accumbens, 
thalamus and hypothalamus compared to healthy controls, with no significant changes 
observed in putamen, globus pallidus and  substantia nigra  (Table e-4; Figures 1A, 2 
and 3). Within the thalamus, loss of [11C]rolipram VT was driven by prefrontal, 
temporal, posterior parietal and primary sensory thalamic nuclei, with no significant 
changes in motor thalamic nuclei in PD patients compared to healthy controls (Table 
e-4; Figures 1A, 2 and 3).  
 
In the frontal cortex, [11C]rolipram VT was decreased in the precentral gyrus, 
dorsolateral frontal cortex, posterior dorsolateral frontal cortex, medial frontal cortex  
including anterior medial frontal cortex and posterior medial frontal cortex, central 
and frontal operculum and supplementary motor area (Table e-4; Figures 1B, 2 and 
3).  
 
Correlations: PDE4 expression and Spatial Working Memory 
In PD patients, higher number of errors in the spatial working memory test was 
associated with lower [11C]rolipram VT in the precentral gyrus (rs=−0.59; 
Puncor=0.035; Padj=0.045), posterior dorsolateral frontal cortex (rs=−0.62; 
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Puncor=0.032; Padj=0.045), medial frontal cortex (rs=−0.63; Puncor=0.030; Padj=0.045), 
posterior medial frontal cortex (rs=−0.74; Puncor=0.006; Padj=0.036), supplementary 
motor area (rs=−0.69; Puncor=0.012; Padj=0.036), caudate (rs=−0.60; Puncor=0.035; 
Padj=0.045), precommissural caudate (rs=−0.70; Puncor=0.011; Padj=0.036), and 
prefrontal thalamic nuclei (rs=−0.60; Puncor=0.039; Padj=0.045) (Figure 1C). We did 
not find any correlations between frontal cortex nor subcortical nuclei [11C]rolipram 
VT and motor, neuropsychiatric and cognitive measures of psychomotor speed and 
episodic memory (all P>0.10). We also did not find any associations between 
[11C]rolipram VT in all regions examined and disease duration (all P>0.05).  
 
Discussion 
Using [11C]rolipram PET molecular imaging in vivo, we report loss of PDE4 
expression within the striato-thalamo-cortical brain circuitry of PD patients, which is 
associated with spatial working memory deficits. Our findings demonstrate 16-32% 
loss of PDE4 expression in the striatum, thalamus, hypothalamus and frontal cortex of 
PD patients who had episodic and working memory deficits, were on dopamine-
replacement therapy, but had no significant brain atrophy in the regions of interest 
examined.  
 
PDE4 expression was decreased by 12-32% within the thalamus with most marked 
decreases observed in prefrontal and temporal lobe-projecting thalamic nuclei, 
whereas motor nuclei were less affected. Within the cortex PDE4 expression in PD 
patients were decreased by 11-20% with most marked decreases observed in the 
posterior dorsolateral frontal cortex, medial frontal cortex and supplementary motor 
area, whereas the orbitofrontal cortex and frontal operculum were the least affected. 
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We found lower PDE4 expression also in occipital regions but this did not reach the 
statistical significance probably due to the high inter-subject variability in 
[11C]rolipram VT observed in these cortical regions. 
 
We found no differences in cortical and subcortical volumetric measures between PD 
patients and healthy controls. It is possible that the group comparisons were 
insufficiently powered to detect significant differences in cortical and subcortical 
volumetric measures between the PD patients and the healthy controls. Moreover, our 
group of PD patients included early and advanced stages of the disease with some PD 
patients showing motor complications such as levodopa-induced dyskinesias (LIDs). 
Although cortical thinning has been associated with longer PD duration (16), PD 
patients with LIDs exhibited increased cortical thickness in the frontal cortex (17) and 
subcortical nuclei (18). This could have also contributed to the lack of significant 
volumetric changes observed in our cohort of PD patients. We also acknowledge as 
limitation of this study that ROIs [11C]rolipram PET analysis was carried out using 
the anatomical CIC atlas whereas cortical and subcortical volumetric changes were 
assessed with Freesurfer, which could have contributed to some differences in terms 
of regions.  
 
There are no previous clinical or preclinical studies investigating the expression of 
PDE4 in PD. Different lines of evidence in experimental animals confirm a clear role 
for PDE4 in modulating cognition, including working memory. PDE4 knockout mice 
show enhanced long-term depression and impaired long-term memory in a fear-
conditioning paradigm (19), and impaired spatial working memory (20). In animal 
models of Huntington’s disease, decreased PDE4 protein levels and PKA hyper-
activation in the hippocampus were associated with spatial memory deficits, 
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suggesting that PDE4-dependent regulation of cAMP/PKA signalling cascade may be 
one molecular mechanism underlying cognitive decline (21).  In mice, intraperitoneal 
administration of the PDE-4 inhibitor rolipram enhanced spatial working memory 
consolidation in the Morris water maze task (22). In rodents, rolipram has been shown 
to improve working memory deficits caused by administration of scopolamine, a 
muscarinic receptor antagonist (23) and MK-801, a NMDA antagonist (24). 
Treatment with PDE4 inhibitors also ameliorated spatial working memory deficits in 
transgenic mouse model of Alzheimer’s disease (25). PDE4 inhibitors related-
increases in cAMP signals lead to memory enhancements, whereas increases in basal 
cAMP levels due to PDE4 loss lead to memory impairments (26). This might explain 
why PDE4 inhibitors are beneficial in improving cognitive deficits in rodents.  
 
In this study we found significant associations between loss of PDE4 expression in 
the caudate, thalamic nuclei and frontal cortices, and spatial working memory deficits 
in PD patients. The striato-thalamo-cortical circuit has been closely linked to spatial 
working memory. The dorsolateral prefrontal cortex is part of the network mediating 
spatial working memory processes (27). The medial frontal cortex plays an important 
role in performance monitoring on subsequent trials and in the implementation of 
associated adjustments in cognitive control (28). Neuroimaging studies have shown a 
close interaction between the posterior medial frontal cortex and dorsolateral 
prefrontal cortex (28). While the posterior medial frontal cortex controls for errors 
and sends the signal for adjustments, the dorsolateral prefrontal cortex in turn 
implements the necessary top-down control (28). This functional interplay is also 
mediated by the supplementary motor area, which plays a role in spatial rehearsal 
(29), and other subcortical structures such as the caudate and thalamic nuclei. Within 
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the caudate, the precommisural dorsal caudate is the area of the striatum that receives 
the largest corticostriatal projections from the dorsolateral prefrontal cortex and is 
involved in spatial memory processes (30). Output from the basal ganglia projects to 
the thalamus which closes the circuit by projecting back to the dorsolateral frontal 
cortex (31). Our findings show that, within the thalamus, loss of PDE4 expression 
only in the subregions connected to the prefrontal cortex is associated with spatial 
working memory deficits in patients with PD.  
 
Cognitive impairment is a very common feature of PD, affecting up to 57% of 
patients within the first 3–5 years after PD diagnosis, and adds significantly to 
patients and carers’ burden (32). Spatial working memory is affected early in the 
course of the disease and may represent one of the pre-motor symptoms of PD. 
Recent evidence has shown that healthy people over the age of 50 who are at risk of 
developing PD (exhibiting hyposmia and dopamine transporter reduction) performed 
worse at cognitive tests assessing spatial working memory (4). Previous functional 
MR and H2
15O PET molecular imaging studies have shown that blood flow is reduced 
in the fronto-striatal circuit while performing working memory tasks in PD patients 
with and without cognitive impairment (3, 33, 34). In agreement with these findings, 
we found significant correlations between worse performance in the spatial working 
memory tests and decreases in PDE4 expression in precentral gyrus, dorsolateral 
prefrontal cortex, medial frontal cortex and precommisural dorsal caudate.  
 
We have recently shown that another PDE, PDE10A, is decreased by 14–28% in the 
striatum and pallidum of moderate/advanced PD patients and loss of PDE10A 
expression is associated with the severity of motor symptoms and complications (35). 
In comparison with PDE10A, which is mainly expressed in the basal ganglia, PDE4 is 
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widely expressed in the cortex and subcortical regions intimately involved in 
cognitive processes (5). Hereby, it is not surprising that we did not find significant 
decreases in PDE4 expression in subcortical nuclei specifically involved in the control 
of movement such as putamen and pallidum. Taking together our previous and recent 
findings, it is likely that while PDE10A plays a role in the control of movement, 
PDE4 is involved in the regulation of cognitive processes and both enzymes are 
decreased in PD patients leading to the manifestation of motor and cognitive 
symptoms.  
 
We did not find correlations between PDE4 expression and disease duration. This 
may be explained by the wide cross-section in disease duration ranging from three to 
25 years of PD duration and the small number of participants. Further longitudinal 
studies investigating PDE4 expression in a larger cohort of PD patients spanning from 
the de novo to advanced stages are needed to elucidate the role of this enzyme in the 
course of the disease. 
 
The PDE4 family is comprised of four isoforms: PDE4A, B, C and D which encode 
for distinct proteins (8). Preclinical studies have shown that distinct subtypes of PDE4 
isoforms differentially modulate synaptic activity and have distinct neurological role 
(19, 20). PDE4B modulates long-term depression and loss of this isoform causes 
impaired spatial working memory (20), whereas PDE4D regulates long-term 
potentiation and loss of this isoform leads to impaired fear conditioning in mice (19). 
[11C]rolipram binds with high affinity to all four PDE4 isoforms (8), thus it was not 
possible to investigate in humans the different role of PDE4 subtypes. 
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In our study we also investigated the effect of age on PDE4 expression in a cohort of 
healthy controls. Preclinical studies have shown age-related reduction of PDE4 
expression in the striatum and cortex of rodents and non-human primates (36, 37). In 
the striatal and cortical brain tissue of aged rats (100 week old), [3H]rolipram binding 
was decreased by 58-69% compared to young rats (10 week old) (36), and 
[11C]rolipram binding was decreased by 20-25% in the striatum and frontal cortex of 
aged monkeys (37).  However, more recent work indicated that age does not affect 
[11C]rolipram VT in cortical and subcortical regions of healthy controls and patients 
with major depressive disorder aged between 18 to 55 years old (38). Our findings are 
in agreement with the previous study in humans, and we report no age-related 
reduction in cortical and subcortical PDE4 expression in healthy controls spanning 
between 26 to 78 years of age. However, it is possible that the small number of 
healthy controls in each group studied could not reach statistical significance and the 
PDE4 age-related changes observed in rodents might be explained by heterogeneity of 
PDE4 isoforms in different species. Further studies evaluating PD4 expression in 
larger cohort of healthy controls spanning from 20 to 80 years of age are needed to 
clarify the effect of age on PDE4 expression. 
 
Our findings show in vivo a novel neurochemical change in PD, which is associated 
with working memory deficits. Novel PDE4 modulating drugs could potentially 
improve cognitive symptoms in PD.  
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FIGURE LEGENDS 
Fig. 1 PDE4 expression in the groups of Parkinson’s disease patients and healthy 
controls. Column bar graphs showing mean [11C]rolipram volume of distribution (VT) 
in (A) subcortical and (B) cortical brain regions between PD patients and healthy 
controls. (C) Correlations between loss of PDE4 expression and spatial working 
memory deficits in patients with PD. Higher number of errors at the spatial working 
memory test was associated with lower [11C]rolipram VT in precentral gyrus, posterior 
dorsolateral frontal cortex, medial frontal cortex, posterior medial frontal cortex, 
supplementary motor area, caudate, precommissural caudate, and prefrontal thalamic 
nuclei. Colour bar reflects range of [11C]rolipram VT intensity. Error bars represent 
mean ± SD. *P<0.05. All P values are Benjamini-Hochberg corrected for multiple 
comparisons.  
 
Fig. 2 Mean cortical and subcortical loss of PDE4 expression in Parkinson’s disease 
patients. Axial, coronal and sagittal (MNI co-ordinates: x = 19, y = −8, z = 4) mean 
summed [11C]rolipram PET images derived from (A) 12 healthy controls and (B) 12 
PD patients in stereotaxic space showing significant loss of [11C]rolipram volume of 
 23 
distribution (VT) in the PD patients. Colour bar reflects range of [
11C]rolipram VT 
intensity. 
 
Fig. 3 Cortical and subcortical loss of PDE4 expression in a Parkinson’s disease 
patient. Axial summed [11C]rolipram PET images for (A) a 69 year-old healthy 
female (MMSE: 30; MoCA: 30; SWM errors: 8) and (B) a  72 year-old female  with a 
seven years history of PD (H&Y: 2; UPDRS-III: 37; MMSE: 27; MoCA: 29; SWM 
errors: 26). Colour bar reflects range of [11C]rolipram volume of distribution (VT) 
intensity. 
 
TABLE 
Table 1 Clinical characteristics of Parkinson’s disease patients 
Subject Sex Age 
(years) 
Disease 
duration1 
PD 
medication 
duration 
(years) 
Daily 
LED 
(mg)2 
Hoehn 
and 
Yahr 
PDQ-
39 
1 M 73.0 9 7.0 605 3 56 
2 F 68.8 7 0.9 560 3 18 
3 F 58.5 3 12.0 150 1 6 
4 M 76.8 7 5.0 150 2 14 
5 M 73.3 10 9.0 400 3 36 
6 M 76.5 9 7.0 1229 2 15 
7 F 80.0 25 21.0 1383 4 75 
8 F 72.6 7 5.0 640 2 55 
 24 
9 M 73.4 17 13.0 4236 4 37 
10 M 74.6 13 11.0 730 2 9 
11 M 70.5 10 9.0 4149.5 4 44 
12 F 54.1 18 15.0 797 2.5 48 
Mean 
±SD 
7M/
5F 
71.0 
(±7.5) 
11.25 
(±6.1) 
9.58  
(±5.3) 
1252.46 
(±1421) 
2.71 
(±1.0) 
34.42 
(±22) 
1From time of first appearance of PD motor symptoms; 2LED: Levodopa Equivalent Dose. 
